Characterization of Human Urinary Metabolites of the Antimalarial Piperaquine
- 1 December 2006
- journal article
- clinical trial
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 34 (12) , 2011-2019
- https://doi.org/10.1124/dmd.106.011494
Abstract
Five metabolites of the antimalarial piperaquine (PQ) (1,3-bis-[4-(7-chloroquinolyl-4)-piperazinyl-1]-propane) have been identified and their molecular structures characterized. After a p.o. dose of dihydroartemisinin-piperaquine, urine collected over 16 h from two healthy subjects was analyzed using liquid chromatography (LC)/UV, LC/tandem mass spectrometry (MS/MS), Fourier transform ion cyclotron resonance (FTICR)/MS, and H NMR. Five different peaks were recognized as possible metabolites [M1, 320 m/z; M2, M3, and M4, 551 m/z (PQ + 16 m/z); and M5, 567 m/z (PQ + 32 m/z)] using LC/MS/MS with gradient elution. The proposed carboxylic M1 has a theoretical monoisotopic molecular mass of 320.1166 m/z, which is in accordance with the FTICR/MS (320.1168 m/z) findings. The LC/MS/MS results also showed a 551 m/z metabolite (M2) with a distinct difference both in polarity and fragmentation pattern compared with PQ, 7-hydroxypiperaquine, and the other 551 m/z metabolites. We suggest that this is caused by N-oxidation of PQ. The results showed two metabolites (M3 and M4) with a molecular ion at 551 m/z and similar fragmentation pattern as both PQ and 7-hydroxypiperaquine; therefore, they are likely to be hydroxylated PQ metabolites. The molecular structures of M1 and M2 were also confirmed using H NMR. Urinary excretion rate in one subject suggested a terminal elimination half-life of about 53 days for M1. Assuming formation rate-limiting kinetics, this would support recent findings that the terminal elimination half-life of PQ has been underestimated previously.This publication has 19 references indexed in Scilit:
- Development and validation of an automated solid phase extraction and liquid chromatographic method for the determination of piperaquine in urineJournal of Pharmaceutical and Biomedical Analysis, 2006
- Pitfalls in Estimating Piperaquine EliminationAntimicrobial Agents and Chemotherapy, 2005
- High throughput assay for the determination of piperaquine in plasmaJournal of Pharmaceutical and Biomedical Analysis, 2005
- A Randomized, Controlled Study of a Simple, Once-Daily Regimen of Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated, Multidrug-Resistant Falciparum MalariaClinical Infectious Diseases, 2005
- Randomized, Controlled Dose‐Optimization Studies of Dihydroartemisinin‐Piperaquine for the Treatment of Uncomplicated Multidrug‐Resistant Falciparum Malaria in ThailandThe Journal of Infectious Diseases, 2004
- Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malariaBritish Journal of Clinical Pharmacology, 2004
- Safety evaluation of fixed combination piperaquine plus dihydroartemisinin (Artekin®) in Cambodian children and adults with malariaBritish Journal of Clinical Pharmacology, 2003
- Efficacy and Safety of Dihydroartemisinin‐Piperaquine (Artekin) in Cambodian Children and Adults with Uncomplicated Falciparum MalariaClinical Infectious Diseases, 2002
- A simple and robust conductive graphite coating for sheathless electrospray emitters used in capillary electrophoresis/mass spectrometryRapid Communications in Mass Spectrometry, 2001
- Metabolism of primaquine by liver homogenate fractionsExperimental and Toxicologic Pathology, 1999